Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karen Steffey

Nurse Practitioner, Adult Health Lyndhurst, OH Nurse Practitioner

NPI 1225129695 CMS profile 10980637

29001 Cedar Rd Ste 201, Lyndhurst, OH 44124

Open in the dashboard

General payments

$144,622

977 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Steffey of Lyndhurst, OH is reported in the CMS Open Payments database as having received $144,622 across 977 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,282 161
2024 General $17,910 157
2023 General $7,528 152
2022 General $51,660 236
2021 General $57,242 271

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Steffey
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Karen Steffey were reported at $10,282. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Karen Steffey Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $57,242 $138 $43–$438 $132
2022 $51,660 $165 $54–$494 $149
2023 $7,528 $178 $61–$549 $160
2024 $17,910 $186 $62–$575 $164
2025 $10,282 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $92,232 327 payments
  2. Biohaven Pharmaceuticals, Inc. $13,086 45 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $11,678 37 payments
  4. Amgen Inc. $9,605 71 payments
  5. Pfizer Inc. $4,662 101 payments
  6. Impel Pharmaceuticals LLC $3,514 13 payments
  7. Teva Pharmaceuticals USA, Inc. $3,011 159 payments
  8. Allergan Inc. $2,627 6 payments
  9. Axsome Therapeutics, Inc. $1,344 12 payments
  10. Lundbeck LLC $806 54 payments
  11. Other $2,057 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125,059 96 payments
  2. Food and Beverage $14,268 860 payments
  3. Travel and Lodging $4,117 14 payments
  4. Honoraria $1,138 1 payment
  5. Education $41 6 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $86,116 252 payments
  2. NURTEC ODT Primary Care $24,764 82 payments
  3. QULIPTA $14,669 93 payments
  4. AIMOVIG $9,605 71 payments
  5. NURTEC ODT Pain $4,469 94 payments
  6. TRUDHESA $3,438 5 payments
  7. AJOVY $2,970 153 payments
  8. Symbravo $1,344 12 payments
  9. ZAVZPRET $1,191 84 payments
  10. BOTOX $956 38 payments
  11. Other $4,311 304 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,077

Median for Nurse Practitioner: 389

Drug cost

$535,441

Median for Nurse Practitioner: $21,885

Branded share of claims

34.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 123 $106,566
Nurtec Odt Rimegepant Sulfate Brand 77 $99,999
Ubrelvy Ubrogepant Brand 60 $78,741
Aimovig Autoinjector Erenumab-Aooe Brand 52 $52,452
Qulipta Atogepant Brand 38 $43,373
Trokendi Xr Topiramate Brand 18 $37,826
Ajovy Autoinjector Fremanezumab-Vfrm Brand 32 $30,123
Botox Onabotulinumtoxina Brand 17 $22,311
Sumatriptan Succinate Generic 159 $17,139
Frovatriptan Succinate Generic 27 $10,815

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$111,462

Of which drugs: $88,343

Medicare patients

78

Average age 71

Services billed

18,356

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 50%
High blood pressure 47%
Depression 37%
Osteoporosis 33%
COPD 18%
Ischemic heart disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 28 17,700 $88,249
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 164 $81

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $11,844
$11,844 60 —
QULIPTA
  • AbbVie, Inc. $4,813
$4,813 38 —
BOTOX
  • AbbVie, Inc. $224
$224 17 17,700
AJOVY
  • Teva Pharmaceuticals USA, Inc. $222
$222 32 —
VYEPTI
  • Lundbeck LLC $196
$196 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

977 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record